| scholarly article | Q13442814 |
| P50 | author | Tanmoy Bhattacharya | Q55414889 |
| David C. Montefiori | Q63302725 | ||
| Lynn Morris | Q70377150 | ||
| Robert C Bollinger | Q87466781 | ||
| Francine E McCutchan | Q87834728 | ||
| Victoria R Polonis | Q89151700 | ||
| Alan Lapedes | Q102311895 | ||
| Bette Korber | Q30505218 | ||
| S Gnanakaran | Q41047925 | ||
| P2093 | author name string | Ming Zhang | |
| Ming Li | |||
| Marcus G Daniels | |||
| Ramesh S Paranjape | |||
| Dennis Ellenberger | |||
| Smita S Kulkarni | |||
| Salvatore T Butera | |||
| Haili Tang | |||
| P2860 | cites work | Full-length gag sequences of HIV type 1 subtype C recent seroconverters from Pune, India | Q48160418 |
| gp120 sequences from HIV type 1 subtype C early seroconverters in India | Q48176679 | ||
| A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants. | Q52337966 | ||
| Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations | Q56880587 | ||
| Multiple aligned sequence editor (MASE) | Q67269453 | ||
| HIV-1 variants in South and South-East Asia | Q72309705 | ||
| Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120 | Q73824497 | ||
| Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1 | Q79316750 | ||
| Subtype B and subtype C HIV type 1 recombinants in the northeastern state of Manipur, India | Q94431195 | ||
| Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Q22242245 | ||
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 | ||
| Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins | Q24517016 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity | Q24675430 | ||
| A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein | Q24681865 | ||
| Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | Q27629806 | ||
| Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design | Q27634018 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion | Q27641682 | ||
| VMD: visual molecular dynamics | Q27860554 | ||
| Timing the ancestor of the HIV-1 pandemic strains | Q28137904 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B | Q28469023 | ||
| Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 | Q28646812 | ||
| A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding | Q28646883 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination | Q29616724 | ||
| Fast and sensitive multiple sequence alignments on a microcomputer | Q29618252 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. | Q30369026 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen | Q33245640 | ||
| Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. | Q33780595 | ||
| Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels | Q33780649 | ||
| Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 | Q33781344 | ||
| Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail | Q33802126 | ||
| Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences | Q33848275 | ||
| Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression | Q33851952 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus | Q33984296 | ||
| Understanding the genetic diversity of HIV-1. | Q34087006 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques | Q34301728 | ||
| Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa | Q34332009 | ||
| Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein | Q34332519 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein | Q34347265 | ||
| Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody | Q34353296 | ||
| Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 | Q34648079 | ||
| Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions | Q35075569 | ||
| Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity | Q35101464 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding | Q35845976 | ||
| Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. | Q35853659 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. | Q35857331 | ||
| Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. | Q35857408 | ||
| Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. | Q35857683 | ||
| Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
| 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response | Q36483956 | ||
| Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing | Q36540055 | ||
| Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization | Q36635390 | ||
| Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions | Q36639214 | ||
| Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection | Q36647820 | ||
| Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity | Q36685270 | ||
| Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41 | Q36694013 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. | Q37072702 | ||
| Genital tract reservoirs | Q37446855 | ||
| Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. | Q38943221 | ||
| Presence in India of HIV type 1 similar to North American strains | Q39383613 | ||
| Transmission of genetically diverse strains of HIV-1 in Pune, India. | Q39464011 | ||
| Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication | Q39485916 | ||
| Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. | Q40191379 | ||
| Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma | Q40311562 | ||
| Alanine scanning mutants of the HIV gp41 loop | Q40419657 | ||
| The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection | Q40433970 | ||
| Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. | Q40468605 | ||
| Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity | Q40546009 | ||
| Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity | Q40561855 | ||
| Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains | Q40621073 | ||
| Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | Q40682865 | ||
| Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. | Q40721814 | ||
| Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. | Q41276031 | ||
| Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies | Q43611862 | ||
| Evidence of a novel B/C recombinant exhibiting unique breakpoints of near full-length HIV type 1 genome from Northeastern India | Q44174151 | ||
| Isolation & preliminary characterization of two HIV-2 strains from Pune, India | Q44626074 | ||
| Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India | Q45729836 | ||
| HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry | Q46170039 | ||
| Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 | ||
| Genetic analysis of Indian HIV-1 nef: subtyping, variability and implications | Q47939217 | ||
| Subtypes of HIV type 1 circulating in India: partial envelope sequences | Q47946760 | ||
| A role for carbohydrates in immune evasion in AIDS. | Q47982875 | ||
| Genetic diversity of HIV type 1 subtype C env gene sequences from India | Q48078350 | ||
| Molecular analysis of gp41 sequences of HIV type 1 subtype C from India | Q48096149 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | India | Q668 |
| HIV | Q15787 | ||
| HIV transmission | Q49029021 | ||
| P304 | page(s) | 505-520 | |
| P577 | publication date | 2009-01-23 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India | |
| P478 | volume | 385 |
| Q34741807 | A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection |
| Q28545185 | An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies |
| Q35580892 | Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate |
| Q35956940 | Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity |
| Q28751926 | Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys |
| Q34057606 | Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study |
| Q33614495 | Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables |
| Q33594304 | Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals |
| Q98906656 | Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection |
| Q40834595 | Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques |
| Q39186163 | Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies |
| Q44106801 | Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China |
| Q36319309 | Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library |
| Q37256644 | Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 |
| Q46532875 | Deep sequencing of near full-length HIV-1 genomes from plasma identifies circulating subtype C and infrequent occurrence of AC recombinant form in Southern India |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q38737604 | Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity. |
| Q42207794 | Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner |
| Q37348096 | Dual-acting stapled peptides target both HIV-1 entry and assembly |
| Q90281664 | Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8 |
| Q40471543 | Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1). |
| Q33504599 | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways |
| Q33749206 | Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission |
| Q42264980 | Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45. |
| Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
| Q37536431 | Genetic signatures of HIV-1 envelope-mediated bystander apoptosis |
| Q33838382 | Genital tract sequestration of SIV following acute infection |
| Q43116285 | HIV N-linked glycosylation site analyzer and its further usage in anchored alignment |
| Q39344552 | HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. |
| Q35826271 | HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes |
| Q34428738 | Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. |
| Q36827300 | Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes |
| Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
| Q57167018 | Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India |
| Q34157802 | Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine |
| Q53695792 | Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11. |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q33887693 | Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? |
| Q30358434 | Passive immunization against HIV/AIDS by antibody gene transfer. |
| Q89592396 | Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation |
| Q38206519 | Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). |
| Q33725673 | Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
| Q36155365 | Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q36364955 | Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity |
| Q59359981 | Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120 |
| Q36172087 | Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase |
| Q59351886 | Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120 |
| Q38816992 | Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor |
| Q37333743 | T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces |
| Q40043429 | Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response |
| Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
| Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
| Q33614365 | Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
Search more.